藤梨根抗肿瘤药效物质和药理活性研究进展

doi:10.11904/j.issn.1002-3070.2022.01.013

Abstract

Abstract: The root of Radix Actinidia chinensis is a traditional Chinese medicine for clearing heat and detoxifying toxins,mainly in the northeast of China,with a small distribution in northern and northwestern China and the Yangtze River basin.The root has attracted close attention from scholars at home and abroad due to its extensive anti-tumor activity.At present,triterpenoids,flavonoids,anthraquinones,steroids,alkaloids,phenylpropanoids and other chemical components have been isolated from the root,and have achieved significant efficacy in malignant tumors such as gastric cancer,intestinal cancer,esophageal cancer,liver cancer,lung cancer,cervical cancer,ovarian cancer,breast cancer,etc.In this paper,the antitumour substances and pharmacological activities of Radix Actinidia chinensis are described in details,with a view to providing references for further research and clinical application of Radix Actinidia chinensis.

Key words: Radix Actinidia chinensis, Anti-tumor effects, Medicinal substance, Pharmacological activity

CLC Number:

MENG Xin, LU Jinyue, ZHANG Ailin, HE Luwen. Research progress on antitumor medicinal substances and pharmacological activities of Radix Actinidia chinensis[J]. Journal of Practical Oncology, 2022, 36(1): 69-73.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.01.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I1/69

References

1 王群,李云秋.中华猕猴桃根化学成分抗肿瘤作用的研究进展[J].华夏医学,2017,30(1):145-148.
2 陈方超,高守红,王志鹏,等.基于UHPLC-Q-TOF-MS/MS技术鉴定藤梨根的化学成分[J].中国药房,2020,31(14):1725-1731.
3 温庆伟,郑妮,陈春霞,等.阳桃根中化学成分类型的试验研究[J].中药与临床,2013,4(2):9-11.
4 Zhou XF,Zhang P,Pi HF,et al.Triterpenoids from the roots of actinidia chinensis[J].Chem Biodiversity,2009,6(8):1202-1207.
5 Wei LB,Ma SY,Liu HX,et al.Cytotoxic triterpenoids from roots of actinidia chinensis[J].Chem Biodiversity,2018,15(2):1-6.
6 张慧莹,王璇,丁婷婷,等.软枣猕猴桃根蒽醌类化合物的提取及其体外抗肿瘤实验[J].中国老年学杂志,2011,31(23):4630-4631.
7 Song WY,Xu GH,Zhang GJ.Effect of actinidia chinensis planch polysaccharide on the growth and apoptosis,and p-p38 expression in human gastric cancer SGC-7901 cells[J].Chin J Integr Med,2014,34(3):329-333.
8 王岚,康琛,杨伟鹏,等.藤梨根正丁醇提取物和总黄酮苷抗肿瘤作用研究[J].中国中药杂志,2010,35(16):2184-2186.
9 Cheng QL,Li HL,Huang ZQ,et al.2β,3β,23-trihydroxy-urs-12-ene-28-olic acid(TUA)isolated from Actinidia chinensis Radix inhibits NCI-H460 cell proliferation by decreasing NF-κB expression[J].Chem Biol Interact,2015,38(240):1-11.
10 Chang J,Case R.Cytotoxic constituents from the root of actinidia chinensis[J].Planta Med,2006,72(2):955-959.
11 Ku CY,Wang YR,Lin HY,et al.Corosolic acid inhibits hepatocellular carcinoma cell Migration by targeting the VEGFR2/Src/FAK pathway[J].PLoS One,2015,10(5):e0126725.
12 曹雯.胃康颗粒联合化疗对胃癌临床疗效的观察[D].南京:南京中医药大学,2020.
13 附舰,陈光伟,刘理礼,等.藤梨根提取物对人胃癌MKN-45细胞增殖及凋亡的影响[J].现代肿瘤医学,2011,19(1):20-22.
14 党辉,牟宗玲,宋锐,等.藤梨根提取物对人胃癌SGC7901细胞增殖抑制的影响[J].中国老年学杂志,2017,37(4):786-788.
15 徐楚韵,张光霁,楼招欢,等.藤梨根有效组分抑制胃癌BGC-823细胞增殖与迁移作用的研究[J].南京中医药大学学报,2018,34(6):602-606.
16 Zhou CX,Wang CL,Yu AL,et al.MiR-630 suppresses breast cancer progression by targeting metadherin[J].Oncotarget,2016,7(2):1288-1299.
17 张广顺,张光霁,廖广辉,等.藤梨根总三萜化合物通过下调N-Cadherin、Snail抑制BGC-823胃癌细胞侵袭的体内外实验研究[J].中华中医药杂志,2016,31(4):1188-1192.
18 陈永杰,史仁杰.藤梨根提取物对大肠癌LoVo细胞增殖的抑制作用及诱导凋亡的影响[J].世界华人消化杂志,2012,20(18):1657-1661.
19 胡兵,沈克平,史秀峰,等.藤梨根对RKO结肠癌细胞失巢凋亡的作用[J].中国实验方剂学杂志,2013,19(16):242-245.
20 Circu ML,Aw TY.Reactive oxygen species,cellular redox systems,and apoptosis[J].Free Radical Biol Med,2010,48(6):749.
21 Hu WL,Wu CC,Yuan CC,et al.Ethanol extracted from radix of actinidia chinensis inhibits human colon tumor through inhibiting notch-signaling pathway[J].J Cancer,2021,12(3):622-629.
22 Zhou YQ,Zhou ZQ,Li HY,et al.Ethanol extract from radix of actinidia chinensis and evodiamine regulated CCR7 expression in SW480 cells[J].Chin J Mod Med,2011,21(3):336-347.
23 董晶,陆宁,史国军.复方藤梨根制剂联合XELIRI方案治疗结肠癌晚期肝转移的临床研究[J].中国中医药科技,2017,24(2):132-134.
24 国宏莉,李江华,李斌,等.两种藤梨根制剂促凋亡作用的实验研究[J].贵州医药,2013,37(8):675-680.
25 Miliaraki M,Briassoulis P,Ilia S,et al.Survivin and caspases serum protein levels and survivin variants mRNA expression in sepsis[J].Sci Rep,2021,11(1):1-11.
26 王涛,关徐涛,王冰,等.藤梨根提取物通过调控miR-451干预人食管鳞癌EC9706细胞的增殖[J].中国老年学杂志,2019,39(7):1666-1669.
27 Abdi E,Latifi-Navid S,Abdi F,et al.Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers[J].Expert Rev Mol Diagn,2020,20(11):1-19.
28 Khordadmehr M,F Jigari‐Asl,Ezzati H,et al.A comprehensive review on miR‐451:A promising cancer biomarker with therapeutic potential[J].J Cell Physiol,2019,234(12):1-16.
29 党辉,关徐涛,宋锐,等.藤梨根提取物与奥沙利铂在诱导人食管癌细胞Ec9706细胞凋亡中的协同作用[J].中华中医药学刊,2017,35(2):286-289.
30 王冰,关徐涛,王涛,等.基于藤梨根提取物调控miR-21干预食管癌细胞Ec9706cDDP的研究[J].时珍国医国药,2015,26(6):1512-1514.
31 Wang Y,Gao XJ,Wei F,et al.Diagnostic and prognostic value of circulating miR-21 for cancer:A systematic review and meta-analysis[J].Gene,2014,533(1):389-397.
32 Pfeffer SR,Yang CH,Pfeffer LM.The role of miR-21 in cancer[J].Drug Dev Res,2015,76(6):270-277.
33 Hou JY,Wang LY,Wu DJ.The root of Actinidia chinensis inhibits hepatocellular carcinomas cells through LAMB3[J].Cell Biol Toxicol,2018,34(4):321-332.
34 He MY,Hou JY,Wang LY,et al.Actinidia chinensis planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9[J].Oncotarget,2017,8(26):42136-42148.
35 Fang TT,Hou JY,He MY,et al.Actinidia chinensis planch root extract(acRoots)inhibits hepatocellular carcinoma progression by inhibiting EP3 expression[J].Cell Biol Toxicol,2016,32(6):1-13.
36 Fang TT,Zhao ZY,Yuan FF,et al.Actinidia chinensis planch root extract attenuates proliferation and metastasis of hepatocellular carcinoma by inhibiting the DLX2/TARBP2/JNK/AKT pathway[J].J Ethnopharmacol,2020,251:474-485.
37 邢海洋,张砚迪,王可心,等.中华猕猴桃根提取物对肝癌细胞Bel-7402的放疗增敏作用[J].实用临床医药杂志,2020,24(7):62-64.
38 马慧利,任中海,李明林,等.藤梨根提取物通过微小RNA-34-5p调控肝癌细胞生物学行为[J].中华实验外科杂志,2019(10):1762-1765.
39 关英,阿选德.藤梨根乙酸乙酯提取物对肺癌A549细胞凋亡的诱导作用[J].中国药房,2015,26(25):3499-3501.
40 袁古治.藤梨根水提取物对人肺癌细胞增殖抑制的影响[J].中医临床研究,2019,11(10):34-36.
41 Wang LY,Hou JY,Shi L.Inhibitory effects of actinidia chinensis planch root extracts(acRoots)on human lung cancer cells through retinoic acid receptor beta[J].Int J Green Nanotechnol,2017,5(2):1-12.
42 Lv JP,Wang LY,Shen H,et al.Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract(acRoots)[J].Cell Biol Toxicol,2018,34(3):207-218.
43 Wang LY,Hou JY,Wang JX,et al.Regulatory roles of HSPA6 in Actinidia chinensis Planch.root extract(acRoots)‐inhibited lung cancer proliferation[J].Clin Transl Med,2020,10(2):1-12.
44 杨誉佳,陆远富,安强,等.藤梨根提取物对宫颈癌的抑制作用[J].中华中医药学刊,2019,37(7):1710-1714.
45 雷蕾.藤梨瞿芪方对人卵巢癌SKOV-3细胞增殖和凋亡的影响[D].宁夏:宁夏医科大学,2020.
46 Liu B,Cui J,Sun J,et al.Immunolocalization of MMP9 and MMP2 in osteolytic metastasis originating from MDA-MB-231 human breast cancer cells[J].Mol Med Rep,2016,14(2):1099-1106.

[1]	WANG Yanping, QIU Lin, WU Meng, SA Rina. Analysis of the incidence and mortality of malignant tumors in Shaanxi province in 2016 [J]. Journal of Practical Oncology, 2022, 36(1): 1-6.
[2]	ZHANG Yiyi, LI Qi, LIU Xu, WANG Yanan, ZOU Yuanjie, ZHOU Huihui, XU Chunyan, SU Shengqi, GE Xin, WANG Tong. Analysis of 5-year survival and its influencing factors of patients with cervical cancer [J]. Journal of Practical Oncology, 2022, 36(1): 7-13.
[3]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[4]	ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(1): 20-25.
[5]	BU Jianlong, ZHANG Pinyi, NI Boxiong, YU Xiran, NING Jinfeng. Analysis of risk factors for lymph node metastasis in early lung adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 26-30.
[6]	ZHAO Baoshan, LIANG Guanying, XU Shengjie, QIAO Hui, CHEN Hongxia, MA Ying, JU Xueping, WANG Lin. Analysis of the correlation between PELP1 expression and gastric cancer progression and prognosis [J]. Journal of Practical Oncology, 2022, 36(1): 31-36.
[7]	LI Weihua, ZHANG Guangfeng, MA Lili, HE Pin, WANG Wen, LI Dingfu. Construction of a breast cancer prognostic model based on metabolism-related genes in the TCGA database [J]. Journal of Practical Oncology, 2022, 36(1): 37-43.
[8]	WANG Yuping, SI Meili, SUN Xiaoxia, GUO Yulin. High expression of HPIP in endometrial carcinoma and its significance in the analysis of survival and prognosis [J]. Journal of Practical Oncology, 2022, 36(1): 44-48.
[9]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[10]	DONG Lina, LIANG Tian, ZHANG Xian, ZHANG Guangmei. Research progress on tropism of ovarian cancer to fat-rich omentum organs [J]. Journal of Practical Oncology, 2022, 36(1): 54-58.
[11]	SHI Jingtong, CHEN Minjie, SUN Yihua. Research progress in the role of malignant tumor-derived exosomes in the M2 polarization of macrophages [J]. Journal of Practical Oncology, 2022, 36(1): 59-63.
[12]	ZHANG Wenjing, LIU Jinshuang, WANG Dan, LI Qingwei, LI Zhiwei. Research status of neoadjuvant therapy for pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 64-68.
[13]	WANG Yang, LI Guodong, TANG Qingchao, LIU Ming. Research progress of acidosis in colorectal malignant tumors [J]. Journal of Practical Oncology, 2022, 36(1): 74-78.
[14]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.
[15]	LI Yujun, LIU Liyang, XIAO Juanjuan, XUE Hua. Prognostic stratification and treatment progress in elderly patients with newly diagnosed multiple myeloma [J]. Journal of Practical Oncology, 2022, 36(1): 84-88.

Research progress on antitumor medicinal substances and pharmacological activities of Radix Actinidia chinensis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments